person · Reporting owner
Ralls-Morrison Desiree
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | SVP, GC and Corp Secretary | February 21, 2021 | February 23, 2021 |
| DICK'S SPORTING GOODS, INC.DKS · Entity 556 | Director | June 10, 2026 | June 12, 2026 |
| MCDONALDS CORPMCD · Entity 2849 | EVP, Chief Legal Officer | May 28, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 21, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,909 |
Ending reported balance
After 2021-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-21 · Exercise / conversion · Acquired 1,324 · Balance 30,298 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2021-02-21 · Tax withholding · Disposed 389 · Balance 29,909 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2023-02-21 | Direct | 2,648 |
Reported balance
After 2021-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-21 · Exercise / conversion · Disposed 1,324 · Balance 2,648 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. |
| Performance Share UnitsSEC Table II · derivative / convertible security · Expires 2022-12-31 | Direct | 6,041 |
Reported balance
After 2021-02-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-02-22 · Grant · Acquired 6,041 · Balance 6,041 F3: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
F3: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.
DICK'S SPORTING GOODS, INC.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 7,422 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 838 · Balance 7,422 F1: Represents restricted unit award granted on June 10, 2026. These units are subject to time-based vesting requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted unit award granted on June 10, 2026. These units are subject to time-based vesting requirements.
MCDONALDS CORP
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,268.12 |
Reported balance
After 2026-05-28 transaction · row 1
1 source rowRow 1 · 2026-05-28 · Sale · Disposed 2,763 · Balance 6,268.12 F1: This transaction was executed in multiple trades ranging from $277.60 to $280.19 per share. The price reported represents the weighted average sales price of this trade. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares sold at each separate price. |
| Phantom StockSEC Table II · derivative / convertible security | IndirectNon-Qualified Benefit Plan | 3,278.25 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,278.25 F2: Each share of phantom stock represents a right to receive the cash value of one share of the Company's common stock. F3: Shares of phantom stock are payable in cash following the reporting person's separation from service with the Company. F4: Includes shares acquired through dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades ranging from $277.60 to $280.19 per share. The price reported represents the weighted average sales price of this trade. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the shares sold at each separate price.
F2: Each share of phantom stock represents a right to receive the cash value of one share of the Company's common stock.
F3: Shares of phantom stock are payable in cash following the reporting person's separation from service with the Company.
F4: Includes shares acquired through dividend reinvestment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2022 Filed May 27, 2022 20:16 UTC Amendment | MCDONALDS CORP MCD · Entity 2849 | Exercise / conversionRestricted Stock Units · Derivative | 5,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011829 · doc1.xml · derivative · entry 4 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Chief Legal Off. and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to acquire one share of McDonald's Corporation common stock. F3 · derivative.exercise_date: On May 17, 2021, Ms. Ralls-Morrison was granted 10,791 RSUs, vesting in two equal installments on the first two anniversaries of the grant date. F3 · derivative.expiration_date: On May 17, 2021, Ms. Ralls-Morrison was granted 10,791 RSUs, vesting in two equal installments on the first two anniversaries of the grant date. Read SEC document |
| May 17, 2022 Filed May 27, 2022 20:16 UTC Amendment | MCDONALDS CORP MCD · Entity 2849 | Tax withholdingCommon Stock | 2,389 | $241.63 | $577,254.07 |
DisclosureSEC source: 0001567619-22-011829 · doc1.xml · nonDerivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Chief Legal Off. and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,126 Read SEC document |
| May 17, 2022 Filed May 27, 2022 20:16 UTC Amendment | MCDONALDS CORP MCD · Entity 2849 | OtherCommon Stock | 119 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011829 · doc1.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Chief Legal Off. and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,515 F2 · price: Settlement of dividend equivalent rights in connection with vested RSUs. Each dividend equivalent right is the economic equivalent of one share of McDonald's Corporation common stock. Read SEC document |
| May 17, 2022 Filed May 27, 2022 20:16 UTC Amendment | MCDONALDS CORP MCD · Entity 2849 | Exercise / conversionCommon Stock | 5,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011829 · doc1.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Chief Legal Off. and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a right to acquire one share of McDonald's Corporation common stock. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:34 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantOptions (Right to Buy) · Derivative | 28,491 | $0.00 Strike: $253.39 | $0.00 |
DisclosureSEC source: 0001567619-22-004742 · doc1.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,491 Underlying: Common Stock · 28,491 shares Expires 2032-02-14 F1 · derivative.exercise_date: Options become exercisable in 25% increments on the first, second, third and fourth anniversary dates of the grant. Read SEC document |
| May 17, 2021 Filed May 19, 2021 19:01 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantRestricted Stock Units · Derivative | 2,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010717 · doc1.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,428 Underlying: Common Stock · 2,428 shares Expires 2024-05-17 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to acquire one share of McDonald's Corporation common stock. F4 · derivative.exercise_date: RSUs vest in full on the third anniversary of the grant date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 19:01 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantRestricted Stock Units · Derivative | 10,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010717 · doc1.xml · derivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,791 Underlying: Common Stock · 10,791 shares Expires 2023-05-17 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to acquire one share of McDonald's Corporation common stock. F3 · derivative.exercise_date: 50% of the RSUs vest on the first anniversary of the grant date and 50% of the RSUs vest on the second anniversary of the grant date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 19:01 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantOptions (Right to Buy) · Derivative | 16,892 | $0.00 Strike: $231.68 | $0.00 |
DisclosureSEC source: 0001567619-21-010717 · doc1.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · EVP, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,892 Underlying: Common Stock · 16,892 shares Expires 2031-05-17 F1 · derivative.exercise_date: Options become exercisable in 25% increments on the first, second, third and fourth anniversary dates of the grant. Read SEC document |
| April 03, 2021 Filed Apr 6, 2021 20:56 UTC | DICK'S SPORTING GOODS, INC. DKS · Entity 556 | GrantCommon Stock, par value $0.01 per share | 2,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001089063-21-000066 · wf-form4_161774251135109.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,810 F1 · shares: Shares of time-based restricted stock, subject to vesting. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003527 · doc4.xml · derivative · entry 4 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041 Underlying: Common Stock · 6,041 shares Expires 2022-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F4 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F4 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F4 · balance_after: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003527 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 Underlying: Common Stock · 1,324 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 389 | $38.03 | $14,793.67 |
DisclosureSEC source: 0001225208-21-003527 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,909 Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003527 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003182 · doc4.xml · derivative · entry 5 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,115 Underlying: Common Stock · 1,704 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 501 | $37.52 | $18,797.52 |
DisclosureSEC source: 0001225208-21-003182 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,974 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003182 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 27,873 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003182 · doc4.xml · derivative · entry 4 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,873 Underlying: Common Stock · 27,873 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:25 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 8,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003182 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,666 Underlying: Common Stock · 8,666 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002710 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,216 Underlying: Common Stock · 1,107 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 325 | $38.39 | $12,476.75 |
DisclosureSEC source: 0001225208-21-002710 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,771 Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002710 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:49 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,268 | $38.85 | $49,261.80 |
DisclosureSEC source: 0001225208-21-002245 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,989 Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:49 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002245 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,257 F1 · shares: On February 15, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2020 and subject to the completion of the concurrent three-year individual service period. On February 9, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 6,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-000241 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,527 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. F1 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. F1 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,127 | $35.95 | $76,465.65 |
DisclosureSEC source: 0001225208-21-000241 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,939 Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-000241 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-014095 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,945 Underlying: Common Stock · 11,472 shares Expires 2022-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,383 | $33.65 | $113,837.95 |
DisclosureSEC source: 0001225208-20-014095 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,539 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-014095 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 21:31 UTC | DICK'S SPORTING GOODS, INC. DKS · Entity 556 | GrantCommon Stock, par value $0.01 per share | 2,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001089063-20-000113 · wf-form4_160081025380639.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,791 F1 · shares: Shares of time-based restricted stock, subject to vesting. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,182 | $39.00 | $46,098.00 |
DisclosureSEC source: 0001225208-20-010897 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,450 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:35 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003571 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,771 Underlying: Common Stock · 4,771 shares Expires 2021-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F2 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F2 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F2 · balance_after: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003298 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,972 Underlying: Common Stock · 1,324 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 391 | $42.62 | $16,664.42 |
DisclosureSEC source: 0001225208-20-003298 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,081 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003298 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 25,442 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002843 · doc4.xml · derivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,442 Underlying: Common Stock · 25,442 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 6,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002843 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819 Underlying: Common Stock · 6,819 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002616 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,323 Underlying: Common Stock · 1,107 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 396 | $42.31 | $16,754.76 |
DisclosureSEC source: 0001225208-20-002616 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,148 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002616 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 4,050 | $45.50 | $184,275.00 |
DisclosureSEC source: 0001225208-20-000301 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,437 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015217 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,417 Underlying: Common Stock · 11,472 shares Expires 2022-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 3,373 | $43.25 | $145,882.25 |
DisclosureSEC source: 0001225208-19-015217 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,487 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015217 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 17,150 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003571 · doc4.xml · derivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,150 Underlying: Common Stock · 17,150 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 5,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003571 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,296 Underlying: Common Stock · 5,296 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 6,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003445 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,527 Underlying: Common Stock · 6,527 shares Expires 2020-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F2 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F2 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F2 · balance_after: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002988 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,430 Underlying: Common Stock · 1,107 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 385 | $40.01 | $15,403.85 |
DisclosureSEC source: 0001225208-19-002988 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,663 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002988 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.